ArticleBMC pregnancy and childbirth2026
Relationship between anti-Müllerian hormone concentration in the peripheral blood of women and aneuploid pregnancy.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundWhile diminished ovarian reserve (DOR) is a risk factor for aneuploid pregnancies, its role in women with a history of aneuploid pregnancy remains poorly understood. Anti-Müllerian hormone (AMH) is an effective biomarker for assessing ovarian reserve. This study evaluated ovarian reserve in women with aneuploid pregnancy history and whether serum AMH concentration is a predictive indicator of aneuploidy risk.
methodsA case-control study was conducted among 82 women with aneuploid pregnancy history and 35 with healthy pregnancies at the Affiliated Hospital of Inner Mongolia Medical University between January 2018 and November 2024. Based on the history of polycystic ovary syndrome (PCOS) before pregnancy, the participants were categorised into case groups 1 (without PCOS, n = 70) and 2 (with PCOS, n = 12). Mann-Whitney U test was used to compare age and AMH levels between the case and control groups. A logistic regression model was employed to analyse the relationship between serum AMH concentration and the occurrence of aneuploidy, whereas receiver operating characteristic curve analysis was used to evaluate the predictive value of serum AMH level for aneuploidy in women. Ovarian reserve in these cases was categorised as DOR (AMH level < 1.2 ng/mL), good ovarian reserve (AMH level 1.2-7 ng/mL), and PCOS tendency (AMH level > 7 ng/mL).
resultsNo significant differences in age and serum AMH concentration were found between the case and control groups (mean age, 32.60 and 31.97 years; mean AMH, 3.47 ng/mL and 3.22 ng/mL, respectively). Women in case group 2 (n = 12) exhibited significantly higher serum AMH concentration (mean AMH, 8.66 ± 3.09 ng/mL vs. 3.22 ± 1.46 ng/mL, p = 0.001), whereas those in case group 1 demonstrated significantly lower levels than the controls (2.58 ± 1.49 ng/mL vs. 3.22 ± 1.47 ng/mL, p = 0.045). Low serum AMH concentrations predicted aneuploid pregnancy (odds ratio: 0.752, 95% confidence interval: 0.570-0.991, p = 0.043), and the area under the predicted risk curve was 0.62. Among the cases, 15.85% presented with DOR.
conclusionsThis study indicates that low AMH concentration may be a high-risk factor for aneuploidy. However, ovarian reserve appears to remain within the normal range in most women with a history of aneuploid pregnancy. These findings provide a new perspective for understanding the occurrence of aneuploidy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.